Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haitripopa
- Development stage
- Phase 4
- Lead developer
- Hengrui Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Haitripopa is an oral, small-molecule thrombopoietin (TPO) receptor agonist. It is approved for the treatment of chronic primary immune thrombocytopenia (ITP) and severe aplastic anemia (SAA) in adults. The drug is also under review for marketing authorization for chemotherapy-induced thrombocytopenia and is in clinical development for non-severe aplastic anemia. Haitripopa works by promoting the proliferation and differentiation of megakaryocytes, thereby increasing platelet production.
- Brand names
- 恒曲
- Other names
- Haitripopa ethanolamine海曲泊帕乙醇胺片
02
Targets
TPOR (Thrombopoietin receptor)
Beyond the preview
Go deeper on Haitripopa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haitripopa.